Mark W. Bruner

1.1k total citations
17 papers, 936 citations indexed

About

Mark W. Bruner is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Mark W. Bruner has authored 17 papers receiving a total of 936 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 4 papers in Cell Biology and 3 papers in Oncology. Recurrent topics in Mark W. Bruner's work include Fibroblast Growth Factor Research (6 papers), Viral Infectious Diseases and Gene Expression in Insects (4 papers) and Virus-based gene therapy research (3 papers). Mark W. Bruner is often cited by papers focused on Fibroblast Growth Factor Research (6 papers), Viral Infectious Diseases and Gene Expression in Insects (4 papers) and Virus-based gene therapy research (3 papers). Mark W. Bruner collaborates with scholars based in United States, France and Denmark. Mark W. Bruner's co-authors include C. Russell Middaugh, David B. Volkin, Carl J. Burke, James A. Ryan, P.K. Tsai, Marian L. Harter, Gautam Sanyal, Pranam Chatterjee, Robert K. Evans and S. J. Flint and has published in prestigious journals such as Science, Journal of Biological Chemistry and The EMBO Journal.

In The Last Decade

Mark W. Bruner

17 papers receiving 905 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark W. Bruner United States 12 729 172 146 139 125 17 936
Inna Gorshkova United States 15 661 0.9× 103 0.6× 99 0.7× 362 2.6× 97 0.8× 25 935
Susan H. Shakin-Eshleman United States 11 640 0.9× 94 0.5× 62 0.4× 101 0.7× 150 1.2× 15 966
Henry J. George United States 13 455 0.6× 266 1.5× 114 0.8× 92 0.7× 308 2.5× 19 842
Kazuyuki Takai Japan 21 1.3k 1.8× 102 0.6× 204 1.4× 46 0.3× 62 0.5× 103 1.6k
Milan Fábry Czechia 21 750 1.0× 160 0.9× 156 1.1× 49 0.4× 164 1.3× 82 1.3k
Bhuvaneshwari Mahalingam United States 9 361 0.5× 343 2.0× 59 0.4× 96 0.7× 343 2.7× 9 917
Toby Price United Kingdom 9 594 0.8× 84 0.5× 167 1.1× 104 0.7× 121 1.0× 11 906
Ryo Morishita Japan 17 1.2k 1.7× 83 0.5× 103 0.7× 94 0.7× 81 0.6× 39 1.6k
Erhard Kopetzki Germany 21 574 0.8× 58 0.3× 77 0.5× 68 0.5× 48 0.4× 29 1.1k
Matthew J. Fivash United States 15 800 1.1× 225 1.3× 113 0.8× 58 0.4× 335 2.7× 26 1.3k

Countries citing papers authored by Mark W. Bruner

Since Specialization
Citations

This map shows the geographic impact of Mark W. Bruner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Bruner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Bruner more than expected).

Fields of papers citing papers by Mark W. Bruner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Bruner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Bruner. The network helps show where Mark W. Bruner may publish in the future.

Co-authorship network of co-authors of Mark W. Bruner

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Bruner. A scholar is included among the top collaborators of Mark W. Bruner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Bruner. Mark W. Bruner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Lubiniecki, A. S., David B. Volkin, M. Marcia Federici, et al.. (2010). Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals. 39(1). 9–22. 63 indexed citations
2.
Joyce, Joseph G., James C. Cook, Donald J. Chabot, et al.. (2005). Immunogenicity and Protective Efficacy of Bacillus anthracis Poly-γ-d-glutamic Acid Capsule Covalently Coupled to a Protein Carrier Using a Novel Triazine-based Conjugation Strategy. Journal of Biological Chemistry. 281(8). 4831–4843. 57 indexed citations
3.
Bruner, Mark W., Allison James, Bernard Beall, et al.. (2003). Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine. Vaccine. 21(21-22). 2698–2703. 4 indexed citations
4.
Evans, Robert K., et al.. (2000). Evaluation of Degradation Pathways for Plasmid DNA in Pharmaceutical Formulations via Accelerated Stability Studies. Journal of Pharmaceutical Sciences. 89(1). 76–87. 100 indexed citations
5.
Bruner, Mark W., J. Goldstein, C. Russell Middaugh, Marvin A. Brooks, & David B. Volkin. (1997). Size exclusion HPLC method for the determination of acidic fibroblast growth factor in viscous formulations. Journal of Pharmaceutical and Biomedical Analysis. 15(12). 1929–1935. 6 indexed citations
6.
Volkin, David B., et al.. (1995). Deamidation of Polyanion‐stabilized Acidic Fibroblast Growth Factor. Journal of Pharmaceutical Sciences. 84(1). 7–11. 11 indexed citations
7.
Tsai, P.K., Carl J. Burke, Mark W. Bruner, et al.. (1995). Enhancing the Avidity of a Human Recombinant Anti-HIV-1 Monoclonal Antibody through Oligomerization. Journal of Pharmaceutical Sciences. 84(7). 866–870. 1 indexed citations
8.
Chavan, Ashok J., Boyd E. Haley, David B. Volkin, et al.. (1994). Interaction of Nucleotides with Acidic Fibroblast Growth Factor (FGF-1). Biochemistry. 33(23). 7193–7202. 29 indexed citations
9.
Tsai, P.K., Mark W. Bruner, Charlotte C. Yu Ip, et al.. (1993). Origin of the Isoelectric Heterogeneity of Monoclonal Immunoglobulin h1B4. Pharmaceutical Research. 10(11). 1580–1586. 45 indexed citations
10.
Tsai, P.K., Karen Thompson, Mark W. Bruner, et al.. (1993). Formulation Design of Acidic Fibroblast Growth Factor. Pharmaceutical Research. 10(5). 649–659. 87 indexed citations
11.
Middaugh, C. Russell, Henryk Mach, Carl J. Burke, et al.. (1992). Nature of the interaction of growth factors with suramin. Biochemistry. 31(37). 9016–9024. 127 indexed citations
12.
Burke, Carl J., Gautam Sanyal, Mark W. Bruner, et al.. (1992). Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase.. Journal of Biological Chemistry. 267(14). 9639–9644. 147 indexed citations
13.
Burke, Carl J., Bryan L. Steadman, David B. Volkin, et al.. (1992). The adsorption of proteins to pharmaceutical container surfaces. International Journal of Pharmaceutics. 86(1). 89–93. 37 indexed citations
14.
Copeland, Robert A., Hanlee P. Ji, Robert W. Williams, et al.. (1991). The structure of human acidic fibroblast growth factor and its interaction with heparin. Archives of Biochemistry and Biophysics. 289(1). 53–61. 111 indexed citations
15.
Chatterjee, Pranam, Mark W. Bruner, S. J. Flint, & Marian L. Harter. (1988). DNA-binding properties of an adenovirus 289R E1A protein.. The EMBO Journal. 7(3). 835–841. 68 indexed citations
16.
Bruner, Mark W., Barbara Dalie, Rudolph Spangler, & Marian L. Harter. (1988). Purification and biological characterization of an adenovirus type 2 E1A protein expressed in Escherichia coli.. Journal of Biological Chemistry. 263(8). 3984–3989. 6 indexed citations
17.
Spangler, Rudolph, Mark W. Bruner, Barbara Dalie, & Marian L. Harter. (1987). Activation of Adenovirus Promoters by the Adenovirus E1A Protein in Cell-Free Extracts. Science. 237(4818). 1044–1046. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Inna Gorshkova Breakdown of academic impact, for papers by Susan H. Shakin-Eshleman Breakdown of academic impact, for papers by Henry J. George Breakdown of academic impact, for papers by Kazuyuki Takai Breakdown of academic impact, for papers by Milan Fábry Breakdown of academic impact, for papers by Bhuvaneshwari Mahalingam Breakdown of academic impact, for papers by Toby Price Breakdown of academic impact, for papers by Ryo Morishita Breakdown of academic impact, for papers by Erhard Kopetzki Breakdown of academic impact, for papers by Matthew J. Fivash
Rankless by CCL
2026